The firm owned 1,880 shares of the medical instruments supplier's stock after buying an additional 640 shares during the period. Dean Inv Ltd Com invested in 166,288 shares or 0.8% of the stock. Looking forward C. R. Bard is expected to benefit from the impending merger with Becton, Dickinson and Company, especially in the areas of medication management and infection prevention.
Since January 31, 2017, it had 0 insider buys, and 28 sales for $33.64 million activity. We believe the latest development will provide benefits to the combined entity and bolster its foothold in the global medical devices market. The Company also has a product group of other products.
(NYSE:BCR) recently. Frank Jr Lupisella, VP reported the sale of 3,622 shares of (BCR). Creative Planning boosted its stake in shares of C.R. Bard by 0.7% in the first quarter. Jefferies Group LLC reiterated a "hold" rating and set a $237.00 price target on shares of C.R. Bard in a research note on Monday, March 27th. Raymond James Financial, Inc. reissued a "market perform" rating and issued a $265.00 price target on shares of C.R. Bard in a research report on Tuesday, April 25th. Zacks Investment Research downgraded C.R. Bard from a "buy" rating to a "hold" rating in a report on Monday. The value of the total investment in C.R. Bard, Inc. increased from $18,000 to $19,000 a change of 5.6% since the last quarter. Ten research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of "Hold" and a consensus price target of $271.31. As of the end of the quarter Mackenzie Financial Corp had bought 218,478 shares growing its stake by 1,323.0%.
About 14,082 shares traded.
The simple 20 day moving average for C. R. Bard, Inc.is 1.08% and the simple 200-day moving average is at 25.79%.
The P/E ratio is now 40.73 and the market cap of the company is 23.18B. The firm had revenue of $938.80 million for the quarter, compared to the consensus estimate of $916.15 million. During the same period in the prior year, the company posted $2.34 EPS. The business's quarterly revenue was up 7.5% compared to the same quarter past year.
According to Zacks, analysts expect that C.R. Bard will report full year earnings of $11.79 per share for the current year, with EPS estimates ranging from $11.63 to $11.91.
The company also recently declared a quarterly dividend, which will be paid on Friday, August 4th. Artemis Invest Mngmt Llp owns 24,890 shares or 0.15% of their USA portfolio. The ex-dividend date has been established as Thursday the 27th of April 2017. Timber Hill Ltd Liability Co owns 1,626 shares or 0% of their USA portfolio.
TRADEMARK VIOLATION NOTICE: This story was first published by Transcript Daily and is the property of of Transcript Daily. The original version of this report can be viewed at https://www.baseball-news-blog.com/2017/07/15/c-r-bard-inc-bcr-upgraded-at-zacks-investment-research-updated.html. Finally, Morgan Stanley downgraded C.R. Bard from an "overweight" rating to an "equal weight" rating in a research report on Monday, April 24th. Another trade for 5,827 shares valued at $1.40M was sold by Khichi Samrat S.
Anchor Capital Advisors Llc increased Pepsico Inc (PEP) stake by 31.11% reported in 2016Q4 SEC filing.
The company is up by 0.02 percent from yesterday's close.
Other large investors also recently modified their holdings of the company. Finally, Pennsylvania Trust Co boosted its stake in shares of C.R. Bard by 2.9% in the first quarter. Pennsylvania Trust Co now owns 1,240 shares of the medical instruments supplier's stock valued at $308,000 after buying an additional 35 shares in the last quarter. Vanguard Group Inc. owned approximately 10.88% of C.R. Bard worth $1,958,858,000 at the end of the most recent reporting period. Contravisory Investment Management Inc. now owns 548 shares of the medical instruments supplier's stock worth $136,000 after buying an additional 426 shares during the last quarter. NY boosted its stake in shares of C.R. Bard by 1.3% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier's stock worth $148,000 after buying an additional 4 shares in the last quarter.
09/15/2016 - Evercore ISI began new coverage on C.R. Bard, Inc. giving the company a "buy" rating. NY continued to hold its stake in shares of C.R. Bard, Inc. The firm owned 64,860 shares of the medical instruments supplier's stock after buying an additional 3,669 shares during the period. Following the completion of the sale, the vice president now directly owns 10,139 shares of the company's stock, valued at $3,082,256.